EP3773548A4 - Activité antitumorale in vitro et de xénogreffe d'un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires - Google Patents

Activité antitumorale in vitro et de xénogreffe d'un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires Download PDF

Info

Publication number
EP3773548A4
EP3773548A4 EP19804326.7A EP19804326A EP3773548A4 EP 3773548 A4 EP3773548 A4 EP 3773548A4 EP 19804326 A EP19804326 A EP 19804326A EP 3773548 A4 EP3773548 A4 EP 3773548A4
Authority
EP
European Patent Office
Prior art keywords
xanthene
halogenated
vitro
solid tumors
tumor activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19804326.7A
Other languages
German (de)
English (en)
Other versions
EP3773548B1 (fr
EP3773548A1 (fr
Inventor
Jamie Singer
Eric A. Wachter
Lucy SWIFT
Chunfen ZHANG
Tanya TRIPPETT
Aru NARENDRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Calgary
Provectus Pharmatech Inc
Original Assignee
University of Calgary
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Calgary, Provectus Pharmatech Inc filed Critical University of Calgary
Publication of EP3773548A1 publication Critical patent/EP3773548A1/fr
Publication of EP3773548A4 publication Critical patent/EP3773548A4/fr
Application granted granted Critical
Publication of EP3773548B1 publication Critical patent/EP3773548B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
EP19804326.7A 2018-05-16 2019-05-15 Activité antitumorale in vitro et de xénogreffe d'un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires Active EP3773548B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672373P 2018-05-16 2018-05-16
PCT/US2019/032435 WO2019222361A1 (fr) 2018-05-16 2019-05-15 Activité antitumorale in vitro et de xénogreffe d'un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires

Publications (3)

Publication Number Publication Date
EP3773548A1 EP3773548A1 (fr) 2021-02-17
EP3773548A4 true EP3773548A4 (fr) 2022-03-30
EP3773548B1 EP3773548B1 (fr) 2023-08-09

Family

ID=68534076

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19804326.7A Active EP3773548B1 (fr) 2018-05-16 2019-05-15 Activité antitumorale in vitro et de xénogreffe d'un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires

Country Status (10)

Country Link
US (2) US11058664B2 (fr)
EP (1) EP3773548B1 (fr)
JP (1) JP7116252B2 (fr)
KR (1) KR20200144562A (fr)
CN (1) CN112996502B (fr)
AU (1) AU2019268353B2 (fr)
CA (1) CA3100358A1 (fr)
ES (1) ES2964399T3 (fr)
MX (1) MX2020011836A (fr)
WO (1) WO2019222361A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
MX2022011765A (es) * 2020-03-26 2022-11-09 Provectus Pharmatech Inc Usos novedosos de xantenos halogenados en oncologia y virologia.
EP4117668A4 (fr) * 2021-04-16 2023-12-06 Provectus Pharmatech, Inc. Composition et méthode de traitement oral de la leucémie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122444A1 (fr) * 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
US20170173079A1 (en) * 2015-12-18 2017-06-22 Provectus Pharmatech, Inc. Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
EP3322441A4 (fr) 2015-07-16 2018-12-19 Bharat Biotech International Limited Compositions de vaccin
JP2018521983A (ja) 2015-07-16 2018-08-09 バイオカイン セラピューティックス リミテッド がんを治療するための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122444A1 (fr) * 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
US20170173079A1 (en) * 2015-12-18 2017-06-22 Provectus Pharmatech, Inc. Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Connecting the dots...Provectus Biopharmaceuticals: Rose Bengal (PV-10) + Oncology + Pediatrics", 8 December 2016 (2016-12-08), pages 1 - 2, XP055891153, Retrieved from the Internet <URL:http://provectuspharmaceuticalsinc.blogspot.com/2016/12/rose-bengalpv-10-oncology-pediatrics.html> [retrieved on 20220214] *
ANONYMOUS: "Provectus Biopharmaceuticals and Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) Announce Acceptance of PV-10 Poster Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting - Provectus Biopharmaceuticals, Inc.", 25 April 2018 (2018-04-25), pages 1 - 2, XP055891166, Retrieved from the Internet <URL:https://www.provectusbio.com/news/press-releases/provectus-pr-20180425-1/> [retrieved on 20220214] *
ANONYMOUS: "Provectus Biopharmaceuticals and Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) Announce PV-10 Abstract at American Society of Clinical Oncology (ASCO) Annual Meeting - Provectus Biopharmaceuticals, Inc.", 17 May 2018 (2018-05-17), pages 1 - 3, XP055891169, Retrieved from the Internet <URL:https://www.provectusbio.com/news/press-releases/provectus-pr-20180517-1/> [retrieved on 20220214] *
ANONYMOUS: "Provectus biopharmaceuticals expands global patent portfolio for cancer combination therapy", GLOBENEWSWIRE.COM, 18 April 2018 (2018-04-18), XP055655311, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2018/04/18/1480692/0/en/PROVECTUS-BIOPHARMACEUTICALS-EXPANDS-GLOBAL-PATENT-PORTFOLIO-FOR-CANCER-COMBINATION-THERAPY.html> [retrieved on 20200107] *
DE KRAKER J ET AL: "IODINE-131 ROSE BENGAL THERAPY IN HEPATOBLASTOMA PATIENTS", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 27, no. 5, 1 January 1991 (1991-01-01), pages 613 - 615, XP008083201, ISSN: 0959-8049 *
MATTHAY KATHERINE K. ET AL: "Neuroblastoma", NATURE REVIEWS DISEASE PRIMERS, vol. 2, no. 1, 10 November 2016 (2016-11-10), XP055891393, Retrieved from the Internet <URL:http://www.nature.com/articles/nrdp201678> DOI: 10.1038/nrdp.2016.78 *
SWIFT L. ET AL: "In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.", JOURNAL OF CLINICAL ONCOLOGY, 20 May 2018 (2018-05-20), pages 1 - 3, XP055891172, Retrieved from the Internet <URL:https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10557> [retrieved on 20220214] *
SWIFT LUCY ET AL: "Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma", ONCOTARGETS AND THERAPY, vol. Volume 12, 1 February 2019 (2019-02-01), pages 1293 - 1307, XP055891128, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=48120> DOI: 10.2147/OTT.S191478 *

Also Published As

Publication number Publication date
KR20200144562A (ko) 2020-12-29
EP3773548B1 (fr) 2023-08-09
JP2021526549A (ja) 2021-10-07
AU2019268353A2 (en) 2020-12-03
WO2019222361A9 (fr) 2019-12-19
ES2964399T3 (es) 2024-04-05
CN112996502B (zh) 2023-10-31
US20190350893A1 (en) 2019-11-21
AU2019268353B2 (en) 2023-05-04
WO2019222361A1 (fr) 2019-11-21
AU2019268353A1 (en) 2020-11-26
CA3100358A1 (fr) 2019-11-21
US11974980B2 (en) 2024-05-07
JP7116252B2 (ja) 2022-08-09
CN112996502A (zh) 2021-06-18
US20210308091A1 (en) 2021-10-07
EP3773548A1 (fr) 2021-02-17
US11058664B2 (en) 2021-07-13
MX2020011836A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
SG11202100704PA (en) Systems and methods for producing gene therapy formulations
EP3923974A4 (fr) Conjugués d&#39;il-2 et méthodes d&#39;utilisation de ceux-ci
EP3773548A4 (fr) Activité antitumorale in vitro et de xénogreffe d&#39;un xanthène halogéné contre des tumeurs solides pédiatriques réfractaires
EP3468657A4 (fr) Système d&#39;enregistrement et de stimulation sans fil d&#39;événements bioélectriques
EP3723513A4 (fr) Probiotiques et métabolites de fermentation pour la prévention et le traitement d&#39;états pathologiques chez des animaux
EP4086258A4 (fr) Dérivé purine et son utilisation médicale
EP3902579A4 (fr) Ecmo et crrt simultanés
EP3768698A4 (fr) Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
EP3971190A4 (fr) Dérivé de pyrimidine condensé avec un hétérocycle et son utilisation
EP3773623A4 (fr) Trans-antigène ciblant les cancers hétérogènes et méthodes d&#39;utilisation associées
EP3909974A4 (fr) Gène mutant du facteur de croissance des hepatocytes humains
EP3972646A4 (fr) Complexes d&#39;apohémoglobine-haptoglobine et leurs procédés d&#39;utilisation
EP3596463A4 (fr) Méthodes diagnostiques et thérapeutiques pour des cancers kras-positifs
SG11202112129SA (en) Drug conjugates and methods of using same
IL280000A (en) Formulations for reducing tumors and methods of using them
EP3348643A4 (fr) Interleukine 12 modifiée et utilisation de celle-ci dans la préparation de médicaments pour le traitement de tumeurs
EP3960766A4 (fr) Agent thérapeutique anti-tumeur et son utilisation
IL289335A (en) New cancer antigens and methods
IL289205A (en) New cancer antigens and methods
EP4072580A4 (fr) Vaccin tumoral personnalisé et son utilisation pour l&#39;immunothérapie du cancer
EP4028094A4 (fr) Interface patient et structure de positionnement et de stabilisation pour l&#39;interface patient
EP4031520A4 (fr) Compositions d&#39;imagerie et thérapeutiques
EP3861219A4 (fr) Moyen de verrouillage et meuble le comprenant
EP3915978A4 (fr) Dérivé de n-benzyl-n-arylsulfonamide, préparation et utilisation associées
EP3753579A4 (fr) Conjugué toxine-anticorps anti-trailr2 et son utilisation pharmaceutique en thérapie anti-tumorale

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/24 20190101ALI20220220BHEP

Ipc: A61K 31/7068 20060101ALI20220220BHEP

Ipc: A61K 31/7048 20060101ALI20220220BHEP

Ipc: A61K 31/704 20060101ALI20220220BHEP

Ipc: A61K 31/475 20060101ALI20220220BHEP

Ipc: A61K 31/4745 20060101ALI20220220BHEP

Ipc: A61K 31/365 20060101ALI20220220BHEP

Ipc: A61P 35/00 20060101ALI20220220BHEP

Ipc: A61K 45/06 20060101ALI20220220BHEP

Ipc: A61K 31/352 20060101AFI20220220BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/343 20060101ALI20230214BHEP

Ipc: A61K 33/24 20060101ALI20230214BHEP

Ipc: A61K 31/7068 20060101ALI20230214BHEP

Ipc: A61K 31/7048 20060101ALI20230214BHEP

Ipc: A61K 31/704 20060101ALI20230214BHEP

Ipc: A61K 31/475 20060101ALI20230214BHEP

Ipc: A61K 31/4745 20060101ALI20230214BHEP

Ipc: A61K 31/365 20060101ALI20230214BHEP

Ipc: A61P 35/00 20060101ALI20230214BHEP

Ipc: A61K 45/06 20060101ALI20230214BHEP

Ipc: A61K 31/352 20060101AFI20230214BHEP

INTG Intention to grant announced

Effective date: 20230306

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20230509

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230718

RIN2 Information on inventor provided after grant (corrected)

Inventor name: JAIN, MOHIT

Inventor name: THAKUR, SATBIR

Inventor name: NARENDRAN, ARU

Inventor name: TRIPPETT, TANYA

Inventor name: ZHANG, CHUNFEN

Inventor name: SWIFT, LUCY

Inventor name: WACHTER, ERIC A.

Inventor name: SINGER, JAMIE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019034729

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230402142

Country of ref document: GR

Effective date: 20231211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231211

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231109

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231209

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2964399

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230809